(Q33485663)

27 July 2017

1 reference

title

Currently available hypolipidaemic drugs and future therapeutic developments (English)

1 reference

27 July 2017

Farmer JA

1

1 reference

PubMed ID

8593127

27 July 2017

Gotto AM Jr

series ordinal

2

1 reference

27 July 2017

1 October 1995

1 reference

Bailliere's clinical endocrinology and metabolism

27 July 2017

1 reference

27 July 2017

9

1 reference

27 July 2017

4

1 reference

27 July 2017

825-847

1 reference

Digitalis intoxication. Treatment with a new steroid-binding resin

27 July 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2895%2980177-4

7 January 2021

Influence of probucol administration on lipoprotein cholesterol and apolipoproteins in normolipemic males

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2895%2980177-4

7 January 2021

Coronary angiographic changes with lovastatin therapy. The Monitored Atherosclerosis Regression Study (MARS).

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2895%2980177-4

7 January 2021

Hemorheologic and coagulative pattern in hypercholesterolemic subjects treated with lipid-lowering drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2895%2980177-4

7 January 2021

Effects of therapy with cholestyramine on progression of coronary arteriosclerosis: results of the NHLBI Type II Coronary Intervention Study

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2895%2980177-4

7 January 2021

A receptor-mediated pathway for cholesterol homeostasis

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2895%2980177-4

7 January 2021

Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2895%2980177-4

7 January 2021

Prolongation of the QT interval induced by probucol: demonstration of a method for determining QT interval change induced by a drug.

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2895%2980177-4

7 January 2021

Probucol. A reappraisal of its pharmacological properties and therapeutic use in hypercholesterolaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2895%2980177-4

7 January 2021

Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2895%2980177-4

7 January 2021

A co-operative trial in the primary prevention of ischaemic heart disease using clofibrate. Report from the Committee of Principal Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2895%2980177-4

7 January 2021

Rhabdomyolysis and renal injury with lovastatin use. Report of two cases in cardiac transplant recipients

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2895%2980177-4

7 January 2021

Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2895%2980177-4

7 January 2021

Regulation of the mevalonate pathway

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2895%2980177-4

7 January 2021

Effects of cholestyramine and colestipol on the plasma concentrations of propranolol

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2895%2980177-4

7 January 2021

Biological and medical aspects of active ileal transport of bile acids

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2895%2980177-4

7 January 2021

The Helsinki Heart Study: central findings and clinical implications

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2895%2980177-4

7 January 2021

Regression of coronary atherosclerosis during treatment of familial hypercholesterolemia with combined drug regimens.

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2895%2980177-4

7 January 2021

Contrasting effects of unmodified and time-release forms of niacin on lipoproteins in hyperlipidemic subjects: clues to mechanism of action of niacin

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2895%2980177-4

7 January 2021

HMG CoA reductase inhibitors lower LDL cholesterol without reducing Lp(a) levels

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2895%2980177-4

7 January 2021

The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2895%2980177-4

7 January 2021

A comparison of the efficacy and toxic effects of sustained- vs immediate-release niacin in hypercholesterolemic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2895%2980177-4

7 January 2021

Role of cholesteryl ester transfer protein in reverse cholesterol transport

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2895%2980177-4

7 January 2021

Effects of probucol on plasma cholesterol, high and low density lipoprotein cholesterol, and apolipoproteins A1 and A2 in adults with primary familial hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2895%2980177-4

7 January 2021

Effect of cholestyramine on the fecal excretion of intravenously administered cholesterol-4-14C and its degradation products in a hypercholesterolemic patient

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2895%2980177-4

7 January 2021

Fulminant hepatic failure after ingestion of sustained-release nicotinic acid.

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2895%2980177-4

7 January 2021

https://api.crossref.org/works/10.1016%2FS0950-351X%2895%2980177-4

1 reference

7 January 2021

Effects of Nicotinic Acid Therapy on Plasma High Density Lipoprotein Subfraction Distribution and Composition and on Apolipoprotein A Metabolism

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2895%2980177-4

7 January 2021

Efficacy and long-term adverse effect pattern of lovastatin

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2895%2980177-4

7 January 2021

Effect of gemfibrozil on composition of lipoproteins and distribution of LDL subspecies

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2895%2980177-4

7 January 2021

Development of femoral atherosclerosis in hypercholesterolemic patients during treatment with cholestyramine and probucol/placebo: Probucol Quantitative Regression Swedish Trial (PQRST): a status report.

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2895%2980177-4

7 January 2021

The role of lipids and antioxidative factors for development of atherosclerosis. The Probucol Quantitative Regression Swedish Trial (PQRST).

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2895%2980177-4

7 January 2021

The effect of probucol on femoral atherosclerosis: The Probucol Quantitative Regression Swedish Trial (PQRST)

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2895%2980177-4

7 January 2021

Effects of monotherapy with an HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriography. The Canadian Coronary Atherosclerosis Intervention Trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2895%2980177-4

7 January 2021

Effects on coronary artery disease of lipid-lowering diet, or diet plus cholestyramine, in the St Thomas' Atherosclerosis Regression Study (STARS)

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2895%2980177-4

7 January 2021

Effects of probucol on xanthomata regression in familial hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2895%2980177-4

7 January 2021

10.1016/S0950-351X(95)80177-4

Identifiers

DOI

1 reference

27 July 2017

1 reference

PubMed ID

8593127